The Tisch Cancer Institute at Mount Sinai | Strategic Alliance Partners

December 23, 2024

With a focus on closing gaps in cancer care for underserved populations, Joseph A. Sparano, MD, FACP, always strives to put patients first—a quality that has become a hallmark of his research and career in oncology.

December 19, 2024

Lunresertib plus camonsertib demonstrated efficacy and safety in heavily pretreated endometrial cancer and platinum-resistant ovarian cancer.

November 26, 2024

Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.

November 26, 2024

Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.

November 26, 2024

Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.

November 26, 2024

Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.

November 26, 2024

Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.

October 07, 2024

Joseph A. Sparano, MD, details the next generation of CDK inhibitors such as BLU-222 targeting CDK2 and PF-07220060 targeting CDK4.

October 07, 2024

Josep Llovet, MD, discusses the effiacy of TACE treatment with or without lenvatinib plus pembrolizumab in intermediate-stage hepatocellular carcinoma.

August 29, 2024

Experts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.

August 29, 2024

Ronan Kelly, MD, MBA, offers insights on the future for HER2-directed antibody-drug conjugates.

August 29, 2024

Ronan Kelly, MD, MBA, offers insights on trastuzumab deruxtecan approval as tumor-agnostic HER2-directed therapy.

August 22, 2024

Key opinion leaders examine promising antibody-drug conjugates (ADCs) in the pharmaceutical development pipeline.

August 22, 2024

Expert clinicians offer strategic guidance on optimal sequencing of antibody-drug conjugates (ADCs) in treatment protocols.

August 15, 2024

Experts provide clinical insights on the management of emetogenicity in patients receiving antibody-drug conjugates.

August 15, 2024

A panel of experts discuss hematologic adverse events associated with antibody-drug conjugate therapies.

August 12, 2024

Fred R. Hirsch, MD, PhD, discusses the pros and cons of completing a tissue biopsy compared with a liquid biopsy in non–small cell lung cancer.

August 12, 2024

Sundar Jagannath, MBBS, discusses the potential use of linvoseltamab in patients with triple-class–exposed, relapsed/refractory multiple myeloma.

August 07, 2024

Fred R. Hirsch, MD, PhD, discusses the role of molecular testing in non–small cell lung cancer.

July 30, 2024

Triparna Sen, PhD, discusses the importance of identifying actionable or targetable biomarkers for the management of small cell lung cancer.